Prognostic factors in early-stage NSCLC: Analysis of the placebo group in the MAGRIT study

Byoung Chul Cho, Tommaso De Pas, Haralabos Kalofonos, Qun Wang, Rodryg Ramlau, Ying Cheng, Fabiana Vitiello, Tanel Laisaar, Eric Vallières, Bartosz Kubisa, Sergey Orlov, Keunchil Park, Channa Debruyne, Johan Vansteenkiste

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background/Aim: The analysis of prognostic factors is important to identify determinants of disease-free survival (DFS) and overall survival (OS) in resected non-small-cell lung cancer (NSCLC). Patients and Methods: We examined baseline characteristics associated with DFS and OS among 757 patients with resected, histologically proven, MAGE-A3-positive Stage IB-IIIA NSCLC assigned to placebo in the MAGRIT study (NCT00480025). We explored characteristics of NSCLC that could predict DFS and OS using Cox regression models. Results: The multivariate analysis showed that lower nodal stage, the presence of squamous cell carcinoma (SCC), a broader surgical resection in patients with SCC, and being female with non-SCC were significantly associated with longer DFS. Lower nodal stage and smaller tumor size were significantly associated with an improved OS. Compared to Other International, enrollment in East Asia was associated with an improved OS in patients with non-SCC. Conclusion: This is the first prognostic factor analysis in NSCLC performed on data from a large prospective study. These results confirm retrospective studies and add that histopathology subtype is a strong determinant of DFS in resected MAGE-A3-positive NSCLC.

Original languageEnglish
Pages (from-to)1403-1409
Number of pages7
JournalAnticancer research
Volume39
Issue number3
DOIs
Publication statusPublished - 2019 Mar 1

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Prognostic factors in early-stage NSCLC: Analysis of the placebo group in the MAGRIT study'. Together they form a unique fingerprint.

  • Cite this

    Cho, B. C., De Pas, T., Kalofonos, H., Wang, Q., Ramlau, R., Cheng, Y., Vitiello, F., Laisaar, T., Vallières, E., Kubisa, B., Orlov, S., Park, K., Debruyne, C., & Vansteenkiste, J. (2019). Prognostic factors in early-stage NSCLC: Analysis of the placebo group in the MAGRIT study. Anticancer research, 39(3), 1403-1409. https://doi.org/10.21873/anticanres.13255